Dr. Eva Schernhammer Photo

Eva Schernhammer, D.P.H., M.D.

Adjunct Professor of Epidemiology, Harvard T.H. Chan School of Public Health
Lecturer on Medicine, Part-time, Brigham and Women's Hospital
Harvard Titles

Adjunct Professor of Epidemiology

Other Affiliations

Channing Division of Network Medicine, Brigham and Women's Hospital

Address

399 Revolution Dr 
STE 922 AR 9W50.39
Somerville, MA 02145

Publications View
Response: Night shift work, light at night, and risk of breast cancer [editorial]
Authors: Schernhammer ES, Colditz GA
J Natl Cancer Inst
Rotating night shifts and risk of breast cancer in women participating in the nurses' health study.
Authors: Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA.
J Natl Cancer Inst
View full abstract on Pubmed
First-line therapy in head and neck cancer with docetaxel/cisplatin
Authors: Baur M, Kienzer H, Schweiger J, DeSantis M, Poehnl R, Schernhammer E, Postner G, Kraus R, Pont J, Schratter-Sehn A, Wicke W, Dittrich CH
Ann Oncol (Pro ESMO, Athens, Greece)
Carboplatin/mitomycin C (MMC) as salvage therapy with intraindividual dose escalation in advanced breast cancer
Authors: Fazeny B, Stubenvoll R, DeSantis M, Poehnl R, Soucek B, Schernhammer E, Postner G, Kienzer H, Kraus R, Pont J, Dittrich CH
Pro ASCO, Los Angeles, CA
Docetaxel/cisplatin as first-line therapy in head and neck cancer
Authors: Kienzer H, Schweiger J, Baur M, DeSantis M, Poehnl R, Gerber E, Soucek B, Schernhammer E, Postner G, Pont J, Schlappack A, Schratter-Sehn A, Wicke W, Dittrich CH
Pro ASCO
Intra-individual dose escalation with carboplatin/mitomycin C in advanced breast cancer
Authors: Kienzer H, Baur M, Faezeny M, DeSantis M, Poehnl R, Schernhammer E, Postner G, Kraus R, Point J, Dittrich C
Ann Oncol (Pro ESMO, Athens, Greece)
Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine.
Authors: Czejka M, Bandak S, Simon D, Schüller J, Weiss C, Schernhammer E.
Z Naturforsch C J Biosci
View full abstract on Pubmed
[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion].
Authors: Czejka M, Schüller J, Schernhammer E, Bandak S.
Pharmazie
View full abstract on Pubmed
Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells.
Authors: Bandak S, Czejka M, Schüller J, Schernhammer E.
Arzneimittelforschung
View full abstract on Pubmed
Dexverapamil to overcome epirubicin resistance in advanced breast cancer.
Authors: Thürlimann B, Kröger N, Greiner J, Mross K, Schüller J, Schernhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H, et al.
J Cancer Res Clin Oncol
View full abstract on Pubmed